Eli Lilly’s Mounjaro Overtakes Novo Nordisk’s Wegovy in UK Market Leadership
Eli Lilly’s Mounjaro has emerged as the leading choice in the UK’s private obesity drug market, outperforming Novo Nordisk’s Wegovy…
UK Market
Read More
Eli Lilly’s Mounjaro has emerged as the leading choice in the UK’s private obesity drug market, outperforming Novo Nordisk’s Wegovy…